Lallukka S, Yki-Järvinen H
Department of Medicine, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
Department of Medicine, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95. doi: 10.1016/j.beem.2016.06.006. Epub 2016 Jun 23.
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of liver disease from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is commonly associated with features of the metabolic/insulin resistance syndrome ('Metabolic/Obese NAFLD') and may therefore predict type 2 diabetes (T2DM). For this review, we searched for prospective studies examining whether NAFLD predicts T2DM, and if so, whether this occurs independently of factors such as age and obesity. These studies included NAFLD diagnosed by ultrasonography (n = 6) or liver enzymes (n = 14). All ultrasonography studies found NAFLD to predict the risk of T2DM independently of age, and in 4 out of 6 studies NAFLD was also a predictor independently of BMI. NAFLD was a predictor of T2DM in all 14 studies where NAFLD was diagnosed by liver enzymes. In 12 of these studies, ALT or AST or GGT were significant predictors of T2DM risk, independently of age and BMI. NAFLD, however, is heterogeneous and may also be caused by common genetic variants. The I148M variant in PNPLA3 and the E167K variant in TM6SF2 are both associated with increased liver fat content, but not features of the metabolic/insulin resistance syndrome. These genetic forms of NAFLD predict NASH and cirrhosis but not T2DM. Taken together these data imply that 'Metabolic/Obese NAFLD' predicts T2DM independently of age and obesity and support the role of hepatic insulin resistance in the pathogenesis of this disease.
非酒精性脂肪性肝病(NAFLD)涵盖了从单纯性脂肪变性到非酒精性脂肪性肝炎(NASH)和肝硬化的一系列肝脏疾病。NAFLD通常与代谢/胰岛素抵抗综合征(“代谢性/肥胖性NAFLD”)的特征相关,因此可能预测2型糖尿病(T2DM)。在本综述中,我们检索了前瞻性研究,以检验NAFLD是否能预测T2DM,如果能,这种预测是否独立于年龄和肥胖等因素。这些研究包括通过超声检查诊断的NAFLD(n = 6)或肝酶诊断的NAFLD(n = 14)。所有超声检查研究均发现NAFLD可独立于年龄预测T2DM风险,并且在6项研究中的4项中,NAFLD也是独立于BMI的预测指标。在所有14项通过肝酶诊断NAFLD的研究中,NAFLD都是T2DM的预测指标。在其中12项研究中,ALT或AST或GGT是T2DM风险的显著预测指标,独立于年龄和BMI。然而,NAFLD具有异质性,也可能由常见的基因变异引起。PNPLA3中的I148M变异和TM6SF2中的E167K变异均与肝脏脂肪含量增加有关,但与代谢/胰岛素抵抗综合征的特征无关。这些基因形式的NAFLD可预测NASH和肝硬化,但不能预测T2DM。综合这些数据表明,“代谢性/肥胖性NAFLD”可独立于年龄和肥胖预测T2DM,并支持肝脏胰岛素抵抗在该疾病发病机制中的作用。